3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Lung Neoplasms
3
Venous Thromboembolism
2
Venous Thrombosis
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
8
Nivolumab
6
Gemcitabine
5
spartalizumab
3
Magnetic Resonance Spectroscopy
3
Cyclophosphamide
3
Azacitidine
3
toripalimab
2
fludarabine
2
epacadostat
2
atezolizumab
2
Therapeutics
2
Sirolimus
2
Paclitaxel
2
Interleukin-2
2
Epoetin Alfa
2
Cisplatin
2
Bevacizumab
2
vocimagene amiretrorepvec
1
vandetanib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
sargramostim
1
sapanisertib
1
ruxolitinib
1
rucaparib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Tinzaparin
×
Thoracic
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled